NVision Raises $55M for Quantum Health Tech Expansion

German quantum technology firm NVision has successfully closed a $55 million Series B funding round, signaling a significant expansion of its ambitions from quantum sensing to full-fledged quantum computing. This latest capital infusion, which brings the company's total funding to $120 million, was anchored by a strategic investment from healthcare giant Abbott. The round also saw participation from prominent investors including Playground Global, Entrée Capital, Matterwave/b2venture, and the European Investment Bank.

Originally founded in 2015, NVision has been revolutionizing medical imaging by developing technologies that visualize cellular metabolism in real-time, moving beyond traditional anatomical representation. Their proprietary quantum-physics-based approach significantly amplifies MRI signals, promising earlier and more precise disease detection, particularly in oncology. The company's flagship platform, POLARIS, leverages quantum technology to boost signals from sugar-based contrast agents by orders of magnitude. This allows standard MRI devices to capture metabolic processes with unprecedented clarity, effectively making cellular activity visible alongside physical structure.

The fresh capital will be instrumental in scaling the global rollout of the POLARIS platform and accelerating the development of NVision's novel quantum computing capabilities. The POLARIS system is already being deployed in leading cancer research institutions such as Memorial Sloan Kettering Cancer Center in New York, the University of Cambridge, and the Technical University of Munich, with plans to have approximately 20 systems operational worldwide by year-end. A key advantage of POLARIS is its seamless integration into existing clinical workflows without requiring specialized quantum expertise.

NVision's strategic pivot into quantum computing stems from a groundbreaking discovery made during the development of POLARIS: a new class of organic molecule-based qubits. These qubits are the foundation for NVision's new quantum computing platform, codenamed PIQC (pronounced "Pixie"). By embedding these qubits into thin films and integrating them directly onto photonic chips, NVision aims to create a scalable pathway to quantum computer construction utilizing established semiconductor manufacturing techniques. This integrated approach, combining quantum computing for drug discovery with POLARIS for real-world biological validation, represents a powerful synergy.

Dr. Sella Brosh, CEO and co-founder of NVision, articulated the company's forward-looking vision: "We envision a future where quantum computers unlock an exponential surge in novel therapeutic hypotheses for diseases that are exceptionally challenging today. By extending our focus to quantum computing, built upon our remarkable new class of organic molecule-based qubits, this future is drawing nearer." The strategic investment from Abbott, a leader in diagnostics, underscores the potential of NVision's technology across the diagnostic spectrum.

Peter Karabatsos, Divisional Vice President of New Technology at Abbott, commented on the investment, highlighting NVision's ability to translate complex quantum science into practical, scalable systems. Similarly, Peter Barrett of Playground Global emphasized NVision's transformative impact on cancer detection and treatment, while Ran Achituv from Entrée Capital lauded the combined sensor and computing platform as a comprehensive solution for quantum-driven healthcare. This convergence of advanced sensing and computing power positions NVision at the forefront of next-generation medical innovation.